SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICUHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ICU stock chart
Technical analysisKey statistics
All statistics- Market cap
- $18.36M
- EPS (TTM)
- -$2.97
- Dividend yield
- None
- 52-week range
- 2.07 – 7.35
- Day range
- 3.33 – 3.72
- Volume / Avg
- 209.11K / 99.80K
- Beta
- —
- Shares outstanding
- 5.26M
52-week range
ICU stock today
Shares of SeaStar Medical (ICU) finished lower on Oct 8 at $3.49, a drop of 6.18% or $0.23 per share, versus the S&P 500's 0.47% decline. Volume was 2.1x the average at 209.11K shares, a sign of unusually heavy trading. Shares are 52.5% below their 52-week high of $7.35, set on Oct 16, 2025 and 68.6% above the 52-week low of $2.07, in the middle of the past year's range.
ICU is up 45.4% year to date, outperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 47.0%. SeaStar Medical has posted a net loss over the last twelve months (EPS of -$2.97), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About SeaStar Medical
Company profileSeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Eric Schlorff
- Headquarters
- Denver, CO
- Employees
- 18
- IPO year
- 2021
- Website
- seastarmedical.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$10.00+186.53%
- Strong buy 1
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
SeaStar Medical peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ESLAEstrella Immunopharma Inc. | 0.4175 | -0.43% | $18.16M | vs ICU |
| AKTXAkari Therapeutics plc ADS | 8.13 | -5.74% | $18.58M | vs ICU |
| NEUPNeuphoria Therapeutics Inc. | 3.35 | -2.05% | $18.13M | vs ICU |
| JSPRJasper Therapeutics Inc. | 0.56 | -1.70% | $18.63M | vs ICU |
| NCELNewcelX Ltd. | 3.11 | +2.47% | $17.96M | vs ICU |
| DYAIDyadic International Inc. | 0.4444 | -2.65% | $17.80M | vs ICU |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 3.11 | -1.11% | $20.00M | vs ICU |
| ACTUActuate Therapeutics Inc. | 0.679 | -6.24% | $16.31M | vs ICU |
Indexes, lists and sector
Appears in lists
SeaStar Medical stock FAQ
What is SeaStar Medical's stock price today?
ICU last traded at $3.49 as of Oct 8, 4:00 PM EDT, down 6.18% on the day. Prices are delayed at least 15 minutes.
Does SeaStar Medical pay a dividend?
No. SeaStar Medical does not currently pay a regular cash dividend.
Who is SeaStar Medical's CEO?
Mr. Eric Schlorff is the chief executive officer of SeaStar Medical Holding Corporation, which has about 18 employees.
Has ICU ever split its stock?
Yes. The most recent ICU stock split was a 1-for-10 split on Jan 5, 2026, one of 2 splits on record.
What is the ICU 52-week high?
The 52-week high for ICU is $7.35 and the 52-week low is $2.07. The stock is currently 52.5% below its high.